HAT therapy for sepsis: A review of the therapeutic rationale and current clinical evaluation status

Yali Sun; Yongfang Yang; Zhuoyi Ye; Tongwen Sun

doi:10.1016/j.jointm.2023.04.003

HAT therapy for sepsis: A review of the therapeutic rationale and current clinical evaluation status

J Intensive Med. 2023 Jun 8;3(4):320-325. doi: 10.1016/j.jointm.2023.04.003. eCollection 2023 Oct 31.

Authors

Yali Sun^{1

2}, Yongfang Yang², Zhuoyi Ye², Tongwen Sun^{1

2}

Affiliations

¹ Department of General ICU, The First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Critical Care Medicine, Zhengzhou Key Laboratory of Sepsis, Zhengzhou 450052, Henan, China.
² Henan Engineering Research Center for Critical Care Medicine, Department of General ICU, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.

Abstract

Vitamin C-based cluster therapy, which involves the combined application of hydrocortisone, vitamin C, and thiamine (HAT), is a recently proposed new treatment option for sepsis on top of conventional treatment. This therapy has a strong theoretical basis, but its clinical efficacy remains inconclusive. This review summarizes the rationale for HAT therapy for sepsis and describes the evaluation of its efficacy in clinical observational studies and randomized controlled trials, with the aim of providing a reference for the future clinical practice application of HAT therapy in sepsis.

Keywords: HAT therapy; Hydrocortisone; Metabolic resuscitation; Sepsis; Thiamine; Vitamin C.

Publication types

Review